Copyright Reports & Markets. All rights reserved.

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Circulating Tumor DNA Diagnostics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Circulating Tumor DNA Diagnostics by Type
    • 1.3.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type in 2022
    • 1.3.3 Test Kits
    • 1.3.4 Reagents
  • 1.4 Global Circulating Tumor DNA Diagnostics Market by Application
    • 1.4.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals
    • 1.4.3 Diagnostics Laboratories
    • 1.4.4 Research Laboratories
    • 1.4.5 Academic Research Institutes
  • 1.5 Global Circulating Tumor DNA Diagnostics Market Size & Forecast
  • 1.6 Global Circulating Tumor DNA Diagnostics Market Size and Forecast by Region
    • 1.6.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Circulating Tumor DNA Diagnostics Market Size by Region, (2018-2029)
    • 1.6.3 North America Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Grail, Inc.
    • 2.1.1 Grail, Inc. Details
    • 2.1.2 Grail, Inc. Major Business
    • 2.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Grail, Inc. Recent Developments and Future Plans
  • 2.2 Guardant Health, Inc.
    • 2.2.1 Guardant Health, Inc. Details
    • 2.2.2 Guardant Health, Inc. Major Business
    • 2.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Guardant Health, Inc. Recent Developments and Future Plans
  • 2.3 Biodesix, Inc.
    • 2.3.1 Biodesix, Inc. Details
    • 2.3.2 Biodesix, Inc. Major Business
    • 2.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Biodesix, Inc. Recent Developments and Future Plans
  • 2.4 Exosome Diagnostics
    • 2.4.1 Exosome Diagnostics Details
    • 2.4.2 Exosome Diagnostics Major Business
    • 2.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Exosome Diagnostics Recent Developments and Future Plans
  • 2.5 Freenome Inc.
    • 2.5.1 Freenome Inc. Details
    • 2.5.2 Freenome Inc. Major Business
    • 2.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Freenome Inc. Recent Developments and Future Plans
  • 2.6 LungLife AI, Inc.
    • 2.6.1 LungLife AI, Inc. Details
    • 2.6.2 LungLife AI, Inc. Major Business
    • 2.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 LungLife AI, Inc. Recent Developments and Future Plans
  • 2.7 Inivata Ltd.
    • 2.7.1 Inivata Ltd. Details
    • 2.7.2 Inivata Ltd. Major Business
    • 2.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Inivata Ltd. Recent Developments and Future Plans
  • 2.8 Personal Genome Diagnostics, Inc.
    • 2.8.1 Personal Genome Diagnostics, Inc. Details
    • 2.8.2 Personal Genome Diagnostics, Inc. Major Business
    • 2.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
  • 2.9 CellMax Life
    • 2.9.1 CellMax Life Details
    • 2.9.2 CellMax Life Major Business
    • 2.9.3 CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
    • 2.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 CellMax Life Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Circulating Tumor DNA Diagnostics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Circulating Tumor DNA Diagnostics by Company Revenue
    • 3.2.2 Top 3 Circulating Tumor DNA Diagnostics Players Market Share in 2022
    • 3.2.3 Top 6 Circulating Tumor DNA Diagnostics Players Market Share in 2022
  • 3.3 Circulating Tumor DNA Diagnostics Market: Overall Company Footprint Analysis
    • 3.3.1 Circulating Tumor DNA Diagnostics Market: Region Footprint
    • 3.3.2 Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
    • 3.3.3 Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Circulating Tumor DNA Diagnostics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
  • 6.2 North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
  • 6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country
    • 6.3.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
  • 7.2 Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
  • 7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country
    • 7.3.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 7.3.3 France Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region
    • 8.3.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2029)
    • 8.3.2 China Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 8.3.5 India Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
  • 9.2 South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
  • 9.3 South America Circulating Tumor DNA Diagnostics Market Size by Country
    • 9.3.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country
    • 10.3.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Circulating Tumor DNA Diagnostics Market Drivers
  • 11.2 Circulating Tumor DNA Diagnostics Market Restraints
  • 11.3 Circulating Tumor DNA Diagnostics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Circulating Tumor DNA Diagnostics Industry Chain
  • 12.2 Circulating Tumor DNA Diagnostics Upstream Analysis
  • 12.3 Circulating Tumor DNA Diagnostics Midstream Analysis
  • 12.4 Circulating Tumor DNA Diagnostics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Circulating Tumor DNA Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Circulating Tumor DNA Diagnostics market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Circulating Tumor DNA Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Circulating Tumor DNA Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Circulating Tumor DNA Diagnostics market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Circulating Tumor DNA Diagnostics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Circulating Tumor DNA Diagnostics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics and Freenome Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Circulating Tumor DNA Diagnostics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Test Kits
    Reagents
    Market segment by Application
    Hospitals
    Diagnostics Laboratories
    Research Laboratories
    Academic Research Institutes
    Market segment by players, this report covers
    Grail, Inc.
    Guardant Health, Inc.
    Biodesix, Inc.
    Exosome Diagnostics
    Freenome Inc.
    LungLife AI, Inc.
    Inivata Ltd.
    Personal Genome Diagnostics, Inc.
    CellMax Life
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Circulating Tumor DNA Diagnostics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Circulating Tumor DNA Diagnostics, with revenue, gross margin and global market share of Circulating Tumor DNA Diagnostics from 2018 to 2023.
    Chapter 3, the Circulating Tumor DNA Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Circulating Tumor DNA Diagnostics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Circulating Tumor DNA Diagnostics.
    Chapter 13, to describe Circulating Tumor DNA Diagnostics research findings and conclusion.

    Buy now